ICS II decreased levels of Aβ1-40 and Aβ1-42 and inhibited inflammatory factors, including IL-1β, TNF-α, cyclooxygenase (COX)-2, and TGF-β1, in AD. This evidence concerns the gene IL1B and Alzheimer disease.